Company profile

Howard W. Robin
Incorporated in
Fiscal year end
Former names
Inhale Therapeutic Systems, Inhale Therapeutic Systems Inc
IRS number

NKTR stock data



9 Aug 19
20 Oct 19
31 Dec 19


Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue 23.32M 28.22M 39.83M 27.76M
Net income -109.91M -118.51M -98.21M -96.14M
Diluted EPS -0.63 -0.68 -0.57 -0.56
Net profit margin -471% -420% -247% -346%
Operating income -110.97M -120.69M -100.3M -98.63M
Net change in cash -4.1M 577K -216.45M -688.86M
Cash on hand 2.29M 6.39M 5.81M 222.26M
Cost of revenue 5.02M 5.44M 7.46M 4.78M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 1.19B 307.71M 165.44M 230.78M
Net income 681.31M -96.69M -153.52M -81.18M
Diluted EPS 3.78 -0.62 -1.1 -0.61
Net profit margin 57.09% -31.42% -92.80% -35.17%
Operating income 687.93M -59.64M -112.86M -29.37M
Net change in cash 1.05M -54.88M 4.07M 43.21M
Cash on hand 5.81M 4.76M 59.64M 55.57M
Cost of revenue 24.41M 30.55M 30.22M 34.1M

Financial data from company earnings reports

Financial report summary

  • We are highly dependent on the success of NKTR-214, our lead immuno-oncology (I-O) candidate. We are executing a broad development program for NKTR-214 and clinical and regulatory outcomes for NKTR-214, if not successful, will significantly harm our business.
  • Delays in clinical studies are common and have many causes, and any significant delay in clinical studies being conducted by us or our partners could result in delay in regulatory approvals and jeopardize the ability to proceed to commercialization.
  • The outcomes from competitive I-O and combination therapy clinical trials, and the discovery and development of new potential oncology therapies, could have a material and adverse impact on the value of our I-O research and development pipeline.
  • Drug development is a long and inherently uncertain process with a high risk of failure at every stage of development.
  • The risk of clinical failure for any drug candidate remains high prior to regulatory approval.
  • If we or our contract manufacturers are not able to manufacture drugs or drug substances in sufficient quantities that meet applicable quality standards, it could delay clinical studies, result in reduced sales or constitute a breach of our contractual obligations, any of which could significantly harm our business, financial condition and results of operations.
  • We purchase some of the starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the partial or complete loss of one of these suppliers could cause production delays, clinical trial delays, substantial loss of revenue and contract liability to third parties.
  • Our manufacturing operations and those of our contract manufacturers are subject to laws and other governmental regulatory requirements, which, if not met, would have a material adverse effect on our business, results of operations and financial condition.
  • If we or our partners do not obtain regulatory approval for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.
  • If NKTR-181 is approved by FDA, the ability to market and promote NKTR-181 will depend on the scope and content of the final FDA-approved labeling, which could have a material and adverse impact on the market potential of NKTR-181.
  • Our results of operations and financial condition depend significantly on the ability of our collaboration partners to successfully develop and market drugs and they may fail to do so.
  • We have substantial future capital requirements and there is a risk we may not have access to sufficient capital to meet our current business plan. If we do not receive substantial milestone or royalty payments from our existing collaboration agreements, execute new high value collaborations or other arrangements, or are unable to raise additional capital in one or more financing transactions, we would be unable to continue our current level of investment in research and development.
  • The commercial potential of a drug candidate in development is difficult to predict. If the market size for a new drug is significantly smaller than we anticipate, it could significantly and negatively impact our revenue, results of operations and financial condition.
  • If government and private insurance programs do not provide payment or reimbursement for our partnered products or proprietary products, those products will not be widely accepted, which would have a negative impact on our business, results of operations and financial condition.
  • If we are unable to establish and maintain collaboration partnerships on attractive commercial terms, our business, results of operations and financial condition could suffer.
  • Our revenue is exclusively derived from our collaboration agreements, which can result in significant fluctuation in our revenue from period to period, and our past revenue is therefore not necessarily indicative of our future revenue.
  • We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.
  • If we, or our partners through our collaborations, are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our products, which would adversely affect our business, results of operations and financial condition.
  • If we are unable to create robust sales, marketing and distribution capabilities or to enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully.
  • We depend on third parties to conduct the clinical trials for our proprietary product candidates and any failure of those parties to fulfill their obligations could harm our development and commercialization plans.
  • We expect to continue to incur substantial losses and negative cash flow from operations and may not achieve or sustain profitability in the future.
  • Significant competition for our polymer conjugate chemistry technology platforms and our partnered and proprietary products and product candidates could make our technologies, products or product candidates obsolete or uncompetitive, which would negatively impact our business, results of operations and financial condition.
  • We may not be able to manage our growth effectively, which could adversely affect our operations and financial performance.
  • Our future depends on the proper management of our current and future business operations and their associated expenses.
  • Because competition for highly qualified technical personnel is intense, we may not be able to attract and retain the personnel we need to support our operations and growth.
  • We are dependent on our management team and key technical personnel, and the loss of any key manager or employee may impair our ability to develop our products effectively and may harm our business, operating results and financial condition.
  • The price of our common stock has, and may continue to fluctuate significantly, which could result in substantial losses for investors and securities class action litigation.
  • We have implemented certain anti-takeover measures, which make it more difficult to acquire us, even though such acquisitions may be beneficial to our stockholders.
  • The indenture governing our 7.75% senior secured notes imposes significant operating and financial restrictions on us and our subsidiaries that may prevent us from pursuing certain business opportunities and restrict our ability to operate our business.
  • Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available.
  • We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.
  • If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.
  • We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities.
  • If we or current or future collaborators or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and civil or criminal penalties.
  • We are involved in legal proceedings and may incur substantial litigation costs and liabilities that will adversely affect our business, financial condition and results of operations.
  • Our internal computer systems, or those of our partners, vendors, CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs or the theft of our confidential information or patient confidential information.
  • The United Kingdom’s withdrawal from the European Union (EU) may have a negative effect on global economic conditions, access to patient markets, and regulatory certainty, which could adversely affect our operations.
  • Global economic conditions may negatively affect us and may magnify certain risks that affect our business.
  • If earthquakes or other catastrophic events strike, our business may be harmed.
Management Discussion
  • Our revenue is derived from our collaboration agreements, under which we may receive product sales revenue, royalties, license fees, milestone and other contingent payments and/or contract research payments. Revenue is recognized when we transfer promised goods or services to our collaboration partners. The amount of upfront fees received under our license and collaboration agreements allocated to continuing obligations, such as manufacturing and supply commitments, is generally recognized as we deliver products or provide development services. As a result, there may be significant variations in the timing of receipt of cash payments and our recognition of revenue. We make our best estimate of the timing and amount of products and services expected to be required to fulfill our performance obligations. Given the uncertainties in research and development collaborations, significant judgment is required by us to make these estimates.
Content analysis ?
H.S. senior Avg
New words: advisory, ADYNOVI, Breakthrough, collected, ELOCTATE, lessor, Letter, Northern, postponement, postponing, unresectable
Removed: dual, ELOCTATETM, kinase, medicine, spleen, SYK, tyrosine